Levetiracetam Tablet, Film Coated
Product Images NDC 67877-770

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 67877-770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lave-cont-1000mg-60tab (Lave Cont 1000mg 60tab)

Label for Levetiracetam Tablets USP 1000 mg, film-coated oral tablets, packaged as 60 tablets. The label includes storage instructions, pharmacist dispensing guidance, and manufacturer information (Alkem Laboratories Ltd., India). Distributed by Ascend Laboratories, LLC, Parsippany, NJ, with the NDC number 67877-771-60 and a barcode. It emphasizes the pharmacist should provide the accompanying medication guide to each patient.*

FDA Label Image

Lave-cont-250mg (Lave Cont 250mg 30tab)

Label for Levetiracetam Tablets, USP 250 mg, film-coated oral tablets in a package of 30 tablets. The label includes storage instructions, pharmacist dispensing guidance, and manufacturing information from Alkem Laboratories Ltd., India, with distribution by Ascend Laboratories, LLC. The National Drug Code (NDC) is 67877-768-30.*

FDA Label Image

Lave-cont-500mg-120tab (Lave Cont 500mg 120tab)

Label for Levetiracetam Tablets USP 500 mg film-coated oral tablets. The label indicates a 120-tablet count, manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ. The label includes pharmacist instructions to dispense a Medication Guide, storage conditions, and a barcode.*

FDA Label Image

Lave-cont-750mg-500tab (Lave Cont 750mg 500tab)

Levetiracetam Tablets USP 750 mg film-coated tablets label showing product information, including dosage strength, manufacturer Alkem Laboratories Ltd., and distributor Ascend Laboratories, LLC. The label directs pharmacists to dispense with a Medication Guide and includes storage instructions, packaging for 500 tablets, and a barcode.*

FDA Label Image

Leve-cart-1000mg (Leve Cart 1000mg)

Label for Levetiracetam Tablets, USP 1000 mg film-coated tablets by Ascend Laboratories, LLC. The carton contains 10 unit-dose tablets. The label includes storage instructions, manufacturer details (Alkem Laboratories Ltd., India), and distributor information (Ascend Laboratories, LLC, Parsippany, NJ). The packaging notes it is Rx only and not child-resistant.*

FDA Label Image

Leve-cart-250mg (Leve Cart 250mg)

Packaging label for Levetiracetam Tablets, USP 250 mg oral film-coated tablets. The unit-dose package contains 10 tablets (1 x 10). Labeler is Ascend Laboratories, LLC, with manufacturing by Alkem Laboratories Ltd., India. The label includes dosage storage instructions, warnings, and a barcode.*

FDA Label Image

Leve-cart-500mg (Leve Cart 500mg)

Levetiracetam Tablets, USP 500 mg film-coated oral tablets unit-dose packaging label by Ascend Laboratories, LLC, containing 10 tablets (1 x 10). The label includes storage instructions, manufacturer information (Alkem Laboratories Ltd., India), and a barcode.*

FDA Label Image

Leve-cart-750mg (Leve Cart 750mg)

Levetiracetam Tablets, USP 750 mg film-coated oral tablets in unit-dose packaging. The label includes the NDC 67877-770-33 and states a pack size of 10 (1 x 10) unit-dose tablets. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC. Storage and warning details are also provided.*

FDA Label Image

Leve-fig-1 (Leve Fig 1)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows increasing patient response percentages from placebo at 7.4%, Levetiracetam 1000 mg/day at 37.1%, to Levetiracetam 3000 mg/day at 39.6%.*

FDA Label Image

Leve-fig-2 (Leve Fig 2)

Bar chart depicting the percentage of patients experiencing an outcome across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The vertical axis shows percentage of patients, with Levetiracetam groups showing higher percentages than placebo.*

FDA Label Image

Leve-fig-3 (Leve Fig 3)

A bar chart comparing the percentage of patients between two groups: Placebo (104 patients) at 14.4%, and Levetiracetam 3000 mg/day (180 patients) at 39.4%. The vertical axis represents the percentage of patients, ranging from 0% to 45%. The chart illustrates a higher patient percentage for the Levetiracetam group compared to placebo.*

FDA Label Image

Leve-fig-4 (Leve Fig 4)

A bar chart comparing the percentage of patients between placebo and levetiracetam groups. The placebo group (N=97) shows 19.6% of patients, while the levetiracetam group (N=101) shows 44.6% of patients, indicating a higher percentage with levetiracetam.*

FDA Label Image

Leve-fig-5 (Leve Fig 5)

A bar chart comparing the percentage of patients in two groups: Placebo (N=51) and Levetiracetam (N=58). The vertical axis shows the percentage of patients ranging from 0% to 45%. The Levetiracetam group has a higher percentage (43.1%) than the Placebo group (19.6%).*

FDA Label Image

Leve-fig-6 (Leve Fig 6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Levetiracetam group shows a higher percentage at 72.2%, while the Placebo group shows 45.2%. The y-axis represents the percentage of patients from 0% to 100%.*

FDA Label Image

Leve-stru (Leve Stru)

Chemical structure diagram of the active ingredient Levetiracetam, showing its molecular framework including a pyrrolidone ring and various side groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.